Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Alexion Pharmaceuticals, Inc. (ALXN): Sound Shore Says the Pharmaceutical Company is Driving Innovation

Sound Shore posted 20 year annualized returns of 7.30% and 7.51% for its Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX), respectively, in its Q1 2019 Investor Letter. You can download a copy of the letter here. The figures go to show that the fund outperformed both the Russel Value and the S&P 500, which posted 6.68% and 6.04% gains, respectively, in the same period. Aside from its performance, the fund commented few stocks in its portfolio, among which was Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

“Meanwhile, specialty pharmaceutical holding Alexion rose 38% for the quarter after the company reported solid earnings and positive new drug developments. A leader in the market for orphan drugs that focus on ultra-rare and life-threatening diseases, Alexion’s extensive research and development platform is driving innovation. We were able to purchase the stock at a below normal 14 times P/E with sustainable cash flow from long-dated patents and a promising pipeline.”

Alexion Pharmaceuticals, Inc. (ALXN): Sound Shore Says the Pharmaceutical Company is Driving Innovation

RAJ CREATIONZS / shutterstock.com

Alexion Pharmaceuticals Inc. is a pharmaceutical company, famous for the drug it developed to treat the rare disorders – paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The drug is called Soliris. YTD, Alexion’s stock is up by 34.31%, and on May 10th it had a closing price of $131.69. The company’s market cap is around $29.53 billion, and it is trading at a P/E ratio of 70.73.

At Q4’s end, a total of 41 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of 11% from the previous quarter. On the other hand, there were a total of 44 hedge funds with a bullish position in ALXN a year ago. With hedgies’ positions undergoing their usual ebb and flow, there exists an “upper tier” of noteworthy hedge fund managers who were boosting their holdings meaningfully (or already accumulated large positions).

More specifically, Baker Bros. Advisors was the largest shareholder of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), with a stake worth $833 million reported as of the end of September. Trailing Baker Bros. Advisors was Iridian Asset Management, which amassed a stake valued at $242.9 million. OrbiMed Advisors, Palo Alto Investors, and D E Shaw were also very fond of the stock, giving the stock large weights in their portfolios.

ALXN

Disclosure: None.

This article is originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...